Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer

Publication date: Available online 10 August 2018Source: Diabetes & Metabolic Syndrome: Clinical Research & ReviewsAuthor(s): Ala'a G. Almagthali, Eman H. Alkhaldi, Afnan S. Alzahrani, Ameera K. Alghamdi, Waleed Y. Alghamdi, Ahmed M. KabelAbstractDipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research